Romesser PB, Sherman EJ, Whiting K, et al. - In this prospective analysis, intensity-modulated radiation therapy (IMRT) was assessed for its efficacy and tolerability both when administered with or without concurrent chemotherapy to treat patients suffering from locally advanced thyroid cancer. Including patients with gross residual or unresectable nonanaplastic thyroid carcinoma, a nonrandomized phase 2 trial of IMRT with or without concurrent doxorubicin was performed. Findings revealed CC-IMRT (concurrent chemotherapy with intensity-modulated radiation therapy) provided excellent locoregional control rates and displayed an acceptable toxicity profile as corroborated by functional evaluations and patient-reported outcomes, thus, CC-IMRT may be preferred over IMRT alone.